# IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer

> **NCT07692750** · PHASE1,PHASE2 · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 56 (estimated)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **DRUG:** IBI343+ capecitabine
- **DRUG:** IBI343+Capecitabine+oxaliplatin

## Key facts

- **NCT ID:** NCT07692750
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-30
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07692750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07692750, "IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07692750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*